Clinical Trial

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations.
Protocol Amendment History 2 changes
critical Trial completed 2026-07-30
minor Completion pushed: 2024-10 -> 2024-10-31 2026-07-30
Trial Details
NCT Number NCT05258279
Lead Sponsor Juntendo University
Collaborators: Merck Sharp & Dohme LLC
Conditions Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation
Enrollment 30 participants
Start Date 2022-07-01
Primary Completion 2023-10-31 (estimated)
Study Completion 2024-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-29